GlassScriptPhysician profile
Stephen Martin Winhusen
NPI 1265488514
$985.52
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $792 · 2020: $194.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $194.31 | 2019-2020 | |
| Pfizer INC. | $178.96 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $101.62 | 2019-2020 | |
| Amgen INC. | $81.44 | 2019-2020 | |
| Lilly USA, LLC | $73.33 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.39 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $47.56 | 2019 | |
| Amarin Pharma, INC. | $35.07 | 2019 | |
| Allergan, INC. | $30.36 | 2019 | |
| Shire North American Group INC | $25.33 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.16 | 2019 | |
| Glaxosmithkline, LLC. | $17.66 | 2019 | |
| Daiichi Sankyo INC. | $17.14 | 2019 | |
| Cranial Technologies, INC | $17.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.92 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $15.14 | 2020 | |
| Sanofi-Aventis U.S. LLC | $14.04 | 2019 | |
| Sanofi Pasteur INC. | $13.05 | 2019 | |
| Merck Sharp & Dohme LLC | $11.75 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $11.29 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Winhusen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.